Avalo CFO reports tax withholding share transaction

Avalo Therapeutics Chief Financial Officer Christopher Ryan Sullivan reported a routine tax-related share disposition.

Rhea-AI Filing Summary

Avalo Therapeutics Chief Financial Officer Christopher Ryan Sullivan reported a routine tax-related share disposition. On the reported date, 138 shares of common stock were withheld at $13.10 per share to satisfy tax obligations tied to equity compensation, rather than sold in the open market. A footnote explains that this event includes 588 shares acquired through the company’s Employee Stock Purchase Plan as part of the same reporting transaction. Following these movements, Sullivan directly holds 40,773 shares of Avalo Therapeutics common stock.

Insider Trade Summary

Exercise Price or Tax Liability: 138 shares

Exercise Price or Tax Liability 1 txn

Insider Sullivan Christopher Ryan

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	138	$13.10	$2K

Holdings After Transaction: Common Stock — 40,773 shares (Direct)

Footnotes (1)

1. F1. Includes 588 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction.

Key Figures

Tax-withheld shares: 138 shares Tax-withholding price: $13.10 per share Post-transaction holdings: 40,773 shares +1 more

4 metrics

Tax-withheld shares 138 shares Common stock delivered for tax liability

Tax-withholding price $13.10 per share Value applied to 138 withheld shares

Post-transaction holdings 40,773 shares Common stock directly held by CFO after transaction

ESPP shares acquired 588 shares Acquired via Employee Stock Purchase Plan in this event

Key Terms

tax-withholding disposition, Employee Stock Purchase Plan, Common Stock

3 terms

tax-withholding disposition financial

"transaction_action: "tax-withholding disposition""

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

Employee Stock Purchase Plan financial

"Includes 588 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Avalo Therapeutics (AVTX) report for its CFO?

Avalo Therapeutics’ CFO Christopher Ryan Sullivan reported a tax-related share disposition. 138 common shares were withheld to cover tax obligations, and the event also included 588 shares acquired via the Employee Stock Purchase Plan, leaving him with 40,773 shares held directly.

Did the Avalo Therapeutics (AVTX) CFO sell shares on the open market?

No, the Form 4 shows a tax-withholding disposition, not an open-market sale. 138 shares were delivered to satisfy tax obligations tied to equity compensation, a common administrative mechanism rather than a discretionary market trade.

How many Avalo Therapeutics (AVTX) shares does the CFO hold after this Form 4?

After the reported transactions, CFO Christopher Ryan Sullivan directly holds 40,773 shares of Avalo Therapeutics common stock. This figure reflects his position following the 138-share tax withholding and the inclusion of 588 shares acquired under the Employee Stock Purchase Plan.

What was the price used for the Avalo Therapeutics (AVTX) tax-withholding shares?

The 138 Avalo Therapeutics common shares used for tax withholding were valued at $13.10 per share. This per-share value is applied solely for the tax-liability settlement associated with the equity compensation event disclosed in the Form 4.

What does the Employee Stock Purchase Plan note mean in the Avalo (AVTX) Form 4?

The footnote states the transaction includes 588 shares acquired under Avalo Therapeutics’ Employee Stock Purchase Plan. This indicates part of the reported activity involved routine employee share purchases, separate from the 138 shares withheld for tax obligations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 04:36 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sullivan Christopher Ryan

(Last) (First) (Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/10/2026		F		138	D	$13.1	40,773(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes 588 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction.

	/s/ Christopher Sullivan	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)